Graft Polymer is a UK incorporated holding company with an innovative research and manufacturing facility based in Slovenia. The core business of the Group comprises polymer modification and drug delivery systems developments. Founded in 2017, the Company is incorporated in England and Wales with a head office in London, United Kingdom and has already introduced more than 50 products to the Market; in particular: grafted polymer modifiers; nano-structured and crosslinking polymer alloys; and a variety of delivery vehicles for pharma and bio applications.
The Group has developed a proprietary set of polymer modification technologies, which can improve existing products and processing methodologies by enhancing performance, simplifying manufacturing, reducing material consumption, widening the choice of feedstocks and reducing costs. The Board expects the Group to continue to develop new and innovative polymer technologies both in-house and in conjunction with key industry players and customers.
The Company listed on the Main Market of the London Stock Exchange in January 2022.
Inaugural Annual Report
Having previously worked with Graft Polymer with the successful production of their IPO prospectus, the Perivan shareholder communications team were delighted to be appointed to produce their inaugural annual report which was published on 5th July 2022.
To view the full annual report, click here.
Perivan specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies, private companies, and open and closed-ended funds.